BDBM303768 6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3,6- diazabicyclo[3.1.1]heptan- 3-yl)pyrazin-2- yl)pyrazolo[1,5- a]pyridine-3- carbonitrile::US10137124, Example 546::US10172851, Example 546::US10555944, Example 546::US10953005, Example 546

SMILES CCOc1cc(-c2cnc(cn2)N2CC3CC(C2)N3Cc2ccc(CC)nc2)c2c(cnn2c1)C#N

InChI Key InChIKey=RDBPLYGJFAIMQI-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 303768   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 23nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 77nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 284nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 23nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 77nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 284nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 23nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 77nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 284nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 23nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 77nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM303768(6-ethoxy-4-(5-(6-((6- ethylpyridin-3- yl)methyl)-3...)
Affinity DataIC50: 284nMAssay Description:RET G810R: The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent